Discover 3,059 paid clinical trials in Brockton, Massachusetts. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,059
Active & Responsive
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
Location: Boston MA, Cincinnati OH, Chicago IL, Nashville TN,
Sponsor: Fresenius Kabi
Sex: All
Age: 0 - 17
Code: NCT06274788
Recruiting
Active & Responsive
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
for
PIK3CA-Related Overgrowth Spectrum (PROS),
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 2+
Code: NCT06789913
Phase 2, Recruiting
Active & Responsive
Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes
for
Diabetes Mellitus, Type 1
Location: Boston MA
Sponsor: Boston Children's Hospital
Sex: All
Age: 5 - 12
Code: NCT05899166
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Boston MA, Stony Brook NY, Stamford CT, Mineola NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06312176
Phase 3, Recruiting
Active & Responsive
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Location: Boston MA, Providence RI, Burlington MA, Peabody MA,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07198074
Phase 3, Recruiting
Active & Responsive
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
for
Ovarian Cancer, Fallopian Tube Cancer
Location: Boston MA, New York NY, Philadelphia PA, Durham NC,
Sponsor: M.D. Anderson Cancer Center
Sex: Female
Age: 18+
Code: NCT05287451
Recruiting
Active & Responsive
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
for
Metastatic Dedifferentiated Liposarcoma,
Location: Boston MA, Waterford CT, Guilford CT, Torrington CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06422806
Phase 3, Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase 1, Recruiting
Active & Responsive
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Location: Boston MA, New Haven CT, Mineola NY, New York NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03816345
Phase 1, Recruiting
Active & Responsive
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
for
Healthy Volunteer, Older Adults (65-85 Years)
Location: Boston MA, New York NY, Atlanta GA, Omaha NE, Aurora CO,
Sponsor: University of Colorado, Denver
Sex: All
Age: 65 - 70+
Code: NCT07516405
Phase 1, Recruiting
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Boston MA, Providence RI, New York NY, Hackensack NJ,
Sponsor: Bicara Therapeutics
Sex: All
Age: 18+
Code: NCT06788990
Phase 2, Phase 3, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Hackensack NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase 3, Recruiting
Active & Responsive
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Philadelphia PA,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT06619587
Phase 1, Recruiting
Active & Responsive
FOG-001 in Locally Advanced or Metastatic Solid Tumors
for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Parabilis Medicines, Inc.
Sex: All
Age: 18+
Code: NCT05919264
Phase 1, Phase 2, Recruiting
Active & Responsive
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
for
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms,
Location: Boston MA, Norfolk VA, Detroit MI, Centerville OH,
Sponsor: Stemline Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05386108
Phase 1, Phase 2, Recruiting
Active & Responsive
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)